ArticleBMB reports2025
mTORC1 and STAT3 signaling are indispensable for in vitro TGFβ1-dependent three-dimensional (3D) tendon constructs.
Article in BMB reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Parameter-screened LED therapy targets STAT3/IL-6 axis to attenuate tendinopathy via dual modulation of inflammation and ECM remodeling.Journal of orthopaedic surgery and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Transforming Growth Factor-β1 (TGFβ1) is an established growth factor that regulates tenocyte differentiation, extracellular matrix production, and cell fate. We previously demonstrated its pivotal role in in vitro 3D tendon constructs formation; however, the downstream signaling mechanisms remain elusive. In this study, we explore the roles of mTORC1 (Mammalian Target of Rapamycin Complex 1) and STAT3 (Signal Transducer and Activator of Transcription 3) in mediating TGFβ1-induced 3D tendon formation using rapamycin (an mTORC1 inhibitor) and stattic (a STAT3 inhibitor). Inhibition of either pathway compromised TGFβ1-induced thickening of the tendon construct, cellular proliferation, and collagen fibrillogenesis. Molecular analyses revealed that mTORC1-STAT3 signaling partially mediates TGFβ1-induced Scx expression and tenocyte elongation in the peripheral layer of 3D tendon constructs. Moreover, TGFβ1 treatment augmented mTOR and STAT3 phosphorylation, while inhibition of mTORC1 signaling attenuated TGFβ1-induced STAT3 phosphorylation. These findings underscore the TGFb1-mTORC1-STAT3 signaling pathway as integral to 3D tendon constructs. Overall, our study identifies the mTORC1-STAT3 axis as a crucial mediator of TGFβ1-driven in vitro tendon formation, highlighting its importance in tendon maturation and extracellular matrix organization. [BMB Reports 2025; 58(6): 257-263].
Indexed as
Identifiers
40495482PMC12207444What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.